Some medical breakthroughs begin in a laboratory.
The story of phenylketonuria, or PKU, began somewhere more ordinary: with a mother who wanted to know why her children were so different.
In 1934, Norwegian physician and biochemist Asbjørn Følling investigated two siblings with intellectual disability after their mother brought their puzzling condition to medical attention. What he found was something medicine had not previously recognized: a previously unknown metabolic disorder associated with an unusual chemical substance in the children's urine.
That discovery became the foundation for what is now known as phenylketonuria.
The scientific achievement belonged to Følling, but the story did not begin with a scientist looking for PKU. It began with a parent asking questions, refusing to accept that there was no explanation, and seeking help for her children.
That distinction matters.
The Følling PKU discovery story of 1934 is not simply a story about a chemical test or a medical paper. It is an early and remarkable example of how careful observation, parental advocacy, clinical curiosity, and scientific investigation can intersect to change medical history.
Today, PKU is one of the best-known inherited metabolic disorders, and newborn screening allows many babies with the condition to be identified before symptoms develop. Treatment can begin early, often preventing the severe neurological consequences that historically affected untreated children.
But none of that was known in 1934.
There was no newborn screening program for PKU. There was no established low-phenylalanine diet for affected children. There was no routine blood test used to identify the condition in infants.
There was simply a family with unanswered questions and a physician willing to investigate them.
What Was Discovered in 1934?
In 1934, Asbjørn Følling identified a previously unrecognized metabolic disorder after examining two siblings with intellectual disability and unusual findings in their urine.
The key clue was phenylpyruvic acid, a metabolic product associated with the breakdown of phenylalanine. The condition eventually became known as phenylketonuria, or PKU.
The discovery was important because it connected a neurological condition with an underlying biochemical abnormality.
That was a major shift in medical thinking.
Instead of viewing intellectual disability only as a generalized or unexplained developmental problem, physicians could begin asking whether certain conditions might result from specific disturbances in metabolism.
This idea would become enormously important in the development of biochemical genetics and the broader field of inherited metabolic disease.
The short answer: What did Følling discover?
Følling discovered that certain children with severe developmental and intellectual problems excreted an unusual chemical compound in their urine. He traced the finding to phenylpyruvic acid and recognized the condition as a distinct metabolic disorder.
The disorder became known as phenylketonuria.
The name comes from the presence of phenylketones in the urine. In modern medicine, PKU is understood as an inherited disorder in which the body cannot adequately process the amino acid phenylalanine.
The Mother at the Beginning of the Story
The human part of the PKU discovery story can easily disappear beneath the scientific terminology.
Phenylalanine.
Phenylpyruvic acid.
Metabolism.
Enzymes.
Inherited disease.
Those terms are essential for understanding the science, but they can make the original story sound like an abstract laboratory experiment.
It wasn't.
A mother had two children with significant intellectual disability. She wanted an explanation.
According to accounts of the discovery, the children's mother, often identified in historical sources as Mrs. Borgny Egeland, sought medical help because both of her children had developed in a way that raised questions.
Her persistence brought the unusual family pattern to Følling's attention.
This is one of the most striking aspects of the Asbjørn Følling PKU discovery history: the initial clinical clue was not generated by a large research program. It came from a family.
The mother recognized that something needed explaining.
And she kept looking for an answer.
Why her questions mattered
When one child has an unexplained developmental condition, physicians may consider many possibilities.
When two siblings show a similar unusual pattern, another question emerges:
Could there be something shared by the children?
That could mean an inherited condition. It could point toward an environmental factor. It could suggest a complication during pregnancy or birth. Or it could indicate something medicine has not yet identified.
In 1934, genetics and biochemical medicine were nowhere near their modern forms. The tools available to physicians were limited compared with today's diagnostic technology.
There were no molecular genetic panels.
No tandem mass spectrometry screening.
No sequencing of metabolic genes.
No automated newborn screening cards.
Følling had to work with the information available to him.
And the family history gave him a reason to look more closely.
Who Was Asbjørn Følling?
Asbjørn Følling was a Norwegian physician and professor whose work combined clinical medicine with biochemical investigation.
His background was particularly well suited to the mystery presented by the two children.
This was not simply a case of recognizing a familiar disease. Følling was interested in the chemical processes taking place inside the human body, and that perspective allowed him to pursue a clue that might otherwise have been dismissed.
The children's unusual urine findings became central to his investigation.
Instead of stopping after observing that the children had intellectual disabilities, Følling investigated their metabolism.
That decision changed the course of the case.
The Strange Smell That Became a Scientific Clue
One of the memorable details associated with early descriptions of PKU is the unusual odor of the urine.
Historical accounts describe the urine of affected children as having a distinctive odor. Today, many people associate untreated PKU with a characteristic musty or "mousy" smell.
The smell itself was not the discovery.
It was a clue.
This distinction is important when understanding how medical discoveries happen.
A symptom or physical characteristic may seem insignificant until someone recognizes that it consistently accompanies a particular biological process.
In this case, the unusual urine prompted chemical investigation.
Følling examined the urine and found evidence of a substance that did not fit an ordinary pattern.
That observation opened the door to the discovery.
From observation to chemistry
Følling used chemical testing to investigate the children's urine.
The crucial finding involved phenylpyruvic acid, a compound produced during the metabolism of phenylalanine.
This was the point at which an unexplained clinical problem began to acquire a biochemical identity.
The children did not merely have an unexplained developmental condition.
They had a detectable metabolic abnormality.
And that abnormality could be investigated.
What Is Phenylketonuria?
Phenylketonuria is an inherited metabolic disorder in which the body cannot properly process phenylalanine, an amino acid found in protein-containing foods.
In classic PKU, the underlying problem involves insufficient activity of the enzyme phenylalanine hydroxylase, which normally helps convert phenylalanine into tyrosine.
When that pathway does not work properly, phenylalanine can accumulate in the blood and tissues.
If untreated, elevated phenylalanine can interfere with brain development and neurological function.
The consequences can be severe, particularly when treatment is not started early in life.
This is why early detection is so important.
Why phenylalanine matters
Phenylalanine is not a toxin that healthy people need to avoid.
It is a normal amino acid and an essential component of protein.
The problem in PKU is the body's ability to process it.
A person without PKU can generally regulate phenylalanine through normal metabolic pathways. A person with PKU has a disruption in one of those pathways.
That difference is the biological foundation of the disease.
What happens when PKU is untreated?
Untreated classic PKU can cause severe intellectual disability, developmental delay, seizures, behavioral difficulties, and other neurological problems.
Historically, many children with PKU were not diagnosed until developmental problems had already become apparent.
That timing created a devastating challenge: by the time physicians recognized the problem, significant neurological damage might already have occurred.
The discovery of PKU eventually helped change that model.
Instead of waiting for symptoms, medicine could begin looking for the metabolic abnormality earlier.
That idea ultimately led to newborn screening.
The 1934 Phenylketonuria Discovery Was Only the Beginning
It is tempting to tell the 1934 story as though Følling discovered PKU and the medical problem was solved.
It wasn't.
The 1934 discovery identified the disorder.
Understanding exactly why it occurred took much longer.
Treating it effectively took longer still.
And developing a way to identify affected newborns before symptoms appeared required additional breakthroughs.
This is an important part of PKU early history.
Medical progress is rarely a single moment.
A discovery can create a new question.
Then another scientist answers that question.
That answer creates another problem.
Eventually, those discoveries become a practical treatment or screening program.
PKU followed exactly this pattern.
From Urine Chemistry to an Inherited Disorder
Følling's discovery showed that the children had an unusual metabolic pattern.
The next major scientific question was obvious:
Why?
If the condition occurred in siblings, could heredity be involved?
The answer eventually became clear.
PKU is an inherited disorder, usually caused by pathogenic variants in the PAH gene, which provides instructions for making phenylalanine hydroxylase.
The condition is generally inherited in an autosomal recessive pattern.
That means a child typically inherits a disease-causing variant from both biological parents.
Parents who carry one altered copy generally do not have classic PKU themselves, because they retain another copy that provides sufficient enzyme activity.
This genetic explanation was not available to Følling in the modern molecular sense.
But his discovery provided the biochemical starting point from which later researchers could investigate the inheritance and mechanism of the disorder.
Why the Sibling Pattern Was So Important
The fact that two children in the same family were affected was a major clue.
Imagine a physician seeing one child with unexplained intellectual disability.
There could be countless possible explanations.
Now imagine seeing two siblings with a similar unusual condition.
The probability that the cases share a common cause becomes much more compelling.
This is one reason family history remains such an important part of medical diagnosis.
A patient's symptoms matter.
But patterns across relatives can reveal information that a single case cannot.
In the Følling story, the family pattern helped turn an isolated medical problem into a scientific question.
The Meaning of "Phenylketonuria"
The name phenylketonuria describes a chemical feature of the condition.
"Phenyl" relates to the chemical structure associated with phenylalanine.
"Ketone" refers to the class of compounds that can accumulate as part of the abnormal metabolic pathway.
"Uria" refers to urine.
In other words, the name reflects the presence of phenylketones in urine.
The terminology may sound complicated, but the basic idea is straightforward:
Phenylketonuria is a disorder of phenylalanine metabolism that can result in abnormal phenyl-containing compounds being excreted in urine.
The name itself reflects the chemistry that helped physicians recognize the disease.
When Did Scientists First Recognize PKU as a Disease?
The landmark recognition occurred in 1934, when Følling investigated the two Norwegian siblings and identified the metabolic abnormality that became associated with phenylketonuria.
His initial report described what he called a previously unrecognized form of metabolic disturbance.
At the time, the condition was not yet understood in the way it is today.
There was no modern concept of PAH gene variants or standardized newborn screening.
The 1934 discovery was therefore less about having every answer and more about identifying the existence of a new disease process.
That distinction is important.
Følling found the first crucial piece of the puzzle.
Later researchers would fill in the rest.
Why the 1934 Discovery Was So Important to Medical History
The significance of the discovery goes beyond PKU itself.
Følling's work helped establish a broader principle:
A neurological or developmental disorder may have a measurable biochemical cause.
That concept became foundational to the study of inherited metabolic diseases.
Before the rise of modern biochemical genetics, many developmental disorders were difficult to explain.
Some were categorized primarily by observable symptoms.
But biochemical investigation opened another possibility.
Perhaps the symptoms were the downstream effects of a specific metabolic pathway failing.
PKU became one of the clearest examples of that principle.
A new way to think about unexplained disease
The Følling case encouraged a style of medicine based on asking:
- What chemical process might be abnormal?
- Is there a measurable substance that distinguishes affected patients?
- Does the same abnormality appear in other family members?
- Could the condition be inherited?
- If the metabolic pathway is understood, could changing the diet alter the outcome?
Those questions eventually became central to metabolic medicine.
The Next Breakthrough: Treating PKU Through Diet
Discovering the biochemical abnormality raised another critical question:
Could the disease be treated?
Researchers eventually learned that restricting phenylalanine in the diet could reduce the amount of phenylalanine available to the body.
This led to the development of specialized low-phenylalanine diets for people with PKU.
The logic is relatively simple.
If the body has difficulty processing phenylalanine, reducing dietary phenylalanine can help keep blood levels within a safer range.
But the practical reality is much more complicated.
Phenylalanine is found in protein, and protein is essential for growth and health.
A person with PKU cannot simply eliminate protein from their diet.
Instead, dietary treatment requires carefully controlled nutrition that supplies the amino acids, vitamins, minerals, calories, and other nutrients a person needs while controlling phenylalanine intake.
This is why PKU treatment is generally managed with specialized medical nutrition.
Why Early Treatment Changed Everything
The most important lesson from PKU history may be the difference between treating symptoms after they appear and identifying the disease before irreversible damage occurs.
Historically, children with PKU could appear healthy at birth.
The neurological consequences developed over time.
That created a narrow window in which medicine had to intervene.
If physicians waited for obvious developmental symptoms, it could be too late to prevent severe intellectual disability.
The solution was screening.
The development of newborn screening
In the 1960s, American microbiologist Robert Guthrie developed a practical screening method that made it possible to test newborns for PKU using a small blood sample.
This was a revolutionary change.
Instead of waiting for developmental problems, healthcare systems could identify babies with elevated phenylalanine shortly after birth.
That made early dietary treatment possible.
The Guthrie test became one of the foundations of modern newborn screening programs.
The chain of progress is extraordinary:
A parent raises questions.
A physician investigates.
A chemical abnormality is discovered.
Scientists determine the metabolic mechanism.
Researchers develop dietary treatment.
A screening method is created.
Healthcare systems begin testing newborns.
A disease that once commonly caused severe intellectual disability can now often be identified before symptoms develop.
That is the larger legacy of the 1934 discovery.
The Parent Advocacy Medical Discovery Story Behind PKU
The phrase "parent advocacy" can sometimes sound like a modern healthcare concept.
But the principle is much older.
Parents observe their children every day.
They notice differences in development, behavior, feeding, movement, communication, and physical health.
They often recognize patterns before anyone else does.
That does not mean a parent's interpretation is always medically correct.
It means the observations are valuable data.
The story behind Følling's discovery illustrates that point beautifully.
The mother's role was not to perform the chemical analysis.
It was to make sure the problem did not disappear into the category of "nothing can be done."
She kept seeking an explanation.
That persistence brought the case to a physician whose expertise allowed him to investigate it.
The breakthrough happened where those two forms of knowledge met.
What Parents Can Learn From the Følling Story
The historical lesson is not that every unusual symptom signals a rare disease.
It is not.
Most symptoms have many possible explanations, and modern medical diagnosis requires appropriate clinical evaluation.
The useful lesson is about communication.
If a child has unexplained symptoms or developmental concerns, parents can help clinicians by describing what they have observed as precisely as possible.
For example:
- When did the concern begin?
- Has the child lost a previously acquired skill?
- Do symptoms occur consistently or intermittently?
- Are other family members affected?
- Are there changes in eating, sleep, behavior, movement, or communication?
- Has a symptom appeared after a particular food, medication, infection, or environmental exposure?
- Have multiple healthcare professionals observed the same pattern?
A clear timeline can be surprisingly valuable.
Persistence does not mean ignoring medical advice
There is an important distinction between persistent advocacy and refusing appropriate medical guidance.
Good advocacy means asking respectful questions, requesting clarification, seeking another professional opinion when appropriate, keeping records, and communicating observations clearly.
It does not mean demanding a particular diagnosis.
The historical mother in the PKU story is compelling precisely because she wanted an explanation for something genuinely unexplained.
Her persistence opened a door.
Følling's scientific expertise walked through it.
PKU Symptoms: What Did Physicians Historically Notice?
Untreated PKU can eventually produce significant neurological and developmental symptoms, but affected infants may initially appear relatively normal.
Historically, symptoms became apparent as children grew.
Possible signs of untreated classic PKU can include:
- Developmental delay
- Intellectual disability
- Seizures
- Behavioral or psychiatric difficulties
- Problems with movement or coordination
- Eczema or other skin problems
- A characteristic musty or mousy body or urine odor
- Lighter skin, hair, or eye pigmentation in some affected individuals
These signs are not unique to PKU.
That is one reason relying on symptoms alone is not an effective modern strategy for diagnosing the condition.
Newborn screening exists precisely because PKU can cause harm before obvious symptoms appear.
How Is PKU Diagnosed Today?
Modern PKU diagnosis generally begins with newborn screening.
A small blood sample is collected from a newborn and analyzed for phenylalanine levels and related markers.
If the screening result is abnormal, additional testing is performed.
This may include repeat biochemical testing and, when appropriate, genetic testing.
A screening result is not necessarily the same thing as a final diagnosis.
Babies with abnormal screening results need appropriate follow-up from qualified healthcare professionals.
Why newborn screening matters
The goal of newborn screening is prevention.
The ideal time to identify PKU is before high phenylalanine levels have caused significant neurological consequences.
Early diagnosis allows treatment to begin during a critical period of brain development.
This represents one of the clearest examples of preventive medicine growing out of a historical scientific discovery.
Is PKU Genetic?
Yes.
PKU is an inherited metabolic disorder most commonly associated with changes in the PAH gene.
It is usually inherited in an autosomal recessive pattern.
For a child to have classic PKU, the child generally receives a disease-causing variant from each biological parent.
This explains why siblings can be affected while parents may not show symptoms themselves.
It also explains why identifying one affected child can have implications for genetic counseling and future pregnancies.
Is PKU Curable?
PKU does not currently have a simple cure that permanently removes the underlying genetic cause.
However, it is highly manageable for many people when identified early and treated appropriately.
Treatment traditionally centers on controlling dietary phenylalanine intake while providing adequate nutrition.
Some individuals may also be candidates for medications or other therapies depending on their specific form of PKU, age, treatment history, and clinical circumstances.
Management is individualized.
The key point is that an inherited condition can be managed even when its genetic cause cannot simply be removed.
That is a profound difference from the situation faced by families before newborn screening and modern metabolic treatment existed.
Why the PKU Story Still Matters Today
It is easy to think of a medical discovery as something that belongs entirely to the past.
PKU shows why that view is incomplete.
Every newborn screening test represents the continuation of a scientific chain that began decades earlier.
Every early diagnosis reflects the idea that identifying a disease before symptoms become severe can change a person's future.
Every carefully managed PKU diet reflects the eventual translation of biochemical knowledge into practical care.
And behind the earliest part of that chain was a parent asking why.
The story also offers a broader lesson about how medicine advances.
Scientific progress does not always begin with sophisticated equipment.
Sometimes it begins with a puzzling observation.
Sometimes it begins with a clinician who is curious enough to investigate something unusual.
And sometimes it begins with a parent who says, in effect, "There has to be an explanation."
A Timeline of the Følling PKU Discovery Story
Before 1934: An unexplained condition
Children with what would later be recognized as PKU could develop severe intellectual and neurological problems without a known cause.
There was no routine test for the condition.
1934: Følling investigates two siblings
A Norwegian mother seeks an explanation for her two children with intellectual disability.
The case comes to Asbjørn Følling.
He investigates their urine and identifies an unusual metabolic product.
1934: Phenylpyruvic acid becomes the crucial clue
Chemical analysis reveals phenylpyruvic acid in the children's urine.
Følling recognizes a connection between the biochemical finding and their clinical condition.
Following decades: The disease is studied further
Researchers investigate the disorder's inheritance, metabolism, and biochemical mechanism.
The condition becomes increasingly understood as an inherited metabolic disease.
Mid-20th century: Dietary treatment develops
Researchers discover that controlling phenylalanine intake can help manage the disorder.
Specialized diets become an important part of PKU treatment.
1960s: Newborn screening becomes practical
Robert Guthrie develops a blood-based screening method that makes widespread newborn testing for PKU possible.
Today: Early detection and lifelong management
PKU is routinely included in newborn screening programs in many countries.
Early diagnosis allows treatment to begin before the neurological damage historically associated with untreated PKU occurs.
What Makes the 1934 Discovery Different From Many Medical Breakthroughs?
The Følling story has a particularly compelling structure because the scientific question emerged directly from a family experience.
There was no grand search for a disease called PKU.
There was no research grant titled "Discover Phenylketonuria."
There was a clinical mystery.
That mystery became a biochemical investigation.
And the investigation produced a new disease concept.
This is a useful reminder that medical discoveries often begin with classification.
Before you can treat something, you need to know what it is.
Before you can screen for it, you need a reliable marker.
Before you can develop a targeted treatment, you need to understand the mechanism.
Følling's work provided one of those essential first steps.
The Difference Between Discovery and Modern Understanding
When people search for the "first case" of phenylketonuria, it is worth being precise.
The 1934 report is widely regarded as the landmark discovery of the disorder, but the children were not the first people in history to have PKU.
They were the patients through whom the condition was recognized and scientifically characterized.
That distinction matters because inherited disorders existed long before physicians knew what caused them.
A disease can exist for centuries before medicine identifies it as a distinct condition.
The discovery date is therefore not necessarily the date the disease first appeared in humans.
It is the date when medical science recognized and documented the disorder as a specific clinical and biochemical entity.
How the Følling Story Changed the Way Doctors Think
One of the most important legacies of PKU is diagnostic thinking.
When a patient has a puzzling collection of symptoms, physicians can look beyond individual symptoms and ask whether they form a pattern associated with an underlying metabolic pathway.
That approach is now standard in metabolic medicine.
Inherited metabolic disorders can affect many parts of the body because metabolism is fundamental to every cell.
A defect in one pathway can influence the brain, liver, muscles, skin, development, or energy production.
PKU provided a particularly clear demonstration of how a biochemical defect could produce profound neurological consequences.
What the Story Teaches About Medical Curiosity
Følling did not dismiss the unusual finding.
He investigated it.
That sounds simple, but it is one of the most important habits in science.
Anomalies are valuable.
When something does not fit the expected pattern, it can be tempting to regard it as noise.
But occasionally, the anomaly is the discovery.
The children's unusual urine chemistry was not merely an odd laboratory result.
It was the clue that led to an entirely new understanding of their condition.
The same principle applies across medical research.
Unexpected findings deserve careful attention.
The Human Cost of Delayed Diagnosis
Understanding the history of PKU also means understanding what was at stake.
Before newborn screening and effective early treatment, children with untreated PKU could develop severe intellectual disability.
Families might have been told that a child simply had an unexplained developmental condition.
Without a known biochemical cause, there was little opportunity for targeted treatment.
That history makes modern screening especially significant.
Today, the question is not simply:
"Does this baby eventually develop symptoms?"
The question can be:
"Can we identify the metabolic problem before symptoms appear?"
That is a fundamental transformation in medical care.
From One Family to a Global Screening Principle
The progression from the Norwegian siblings to modern newborn screening is remarkable.
The original discovery involved a tiny number of patients.
The eventual medical application affects millions of newborns.
This is how translational medicine works at its best.
A clinician notices something unusual.
A scientist identifies a mechanism.
Researchers develop a test.
Other researchers establish treatment.
Healthcare systems adopt screening.
A discovery made in one place becomes part of routine preventive care elsewhere.
The people who benefit may never know the name of the physician who made the original observation.
That is often the nature of medical progress.
Why the Story of a Persistent Mother Deserves to Be Remembered
Medical history frequently celebrates the scientist and forgets the patient.
The scientist has a paper.
The institution has an archive.
The discovery has a date.
The patient becomes a case number.
The story of PKU offers an opportunity to tell that history differently.
The mother at the beginning of the story was not the person who identified phenylpyruvic acid.
She did something equally necessary.
She brought an unanswered problem to someone capable of investigating it.
Her insistence created the circumstances in which the scientific discovery could happen.
That does not diminish Følling's achievement.
It makes the story more complete.
The discovery required both human persistence and scientific expertise.
A Practical Lesson for Families Facing Unexplained Medical Problems
The historical story should not be used to encourage self-diagnosis.
Instead, it offers a practical lesson about how to communicate effectively with healthcare professionals.
If you are concerned about an unexplained symptom or developmental change in a child, consider keeping a simple record of:
What happened: Describe the symptom or developmental concern in plain language.
When it happened: Record dates and approximate times when relevant.
How often it happens: Note whether it is constant, occasional, or associated with a particular situation.
What changed: Identify skills or behaviors that were gained, lost, or noticeably altered.
Family history: Tell the healthcare professional about relevant conditions affecting close relatives.
Previous evaluations: Keep track of tests, diagnoses, treatments, and significant findings.
Questions: Write down what you want the clinician to explain before the appointment.
This kind of information can make clinical conversations more productive.
It is a modern expression of the same basic principle that runs through the Følling story: observations matter.
Compassion, Advocacy, and the Broader Meaning of the Story
There is another reason the story resonates beyond medical history.
It is ultimately about compassion.
A parent saw two children whose lives did not fit an easy explanation and refused to stop caring simply because the answer was not immediately available.
A physician encountered a problem that did not have an obvious explanation and chose to investigate.
The result was not immediate perfection.
It was the first step.
That is often what real progress looks like.
The original discovery did not instantly produce modern treatment. It created knowledge that subsequent generations could build upon.
The story therefore connects naturally with broader ideas of compassion, mindful attention, and care for others. For readers interested in ethical and plant-based living, The Dharma Store offers Vegan T-Shirts alongside other designs centered on compassion and conscious living at The Dharma Store.
Frequently Asked Questions About the Følling PKU Discovery Story
Who discovered PKU in 1934?
Norwegian physician and biochemist Asbjørn Følling is credited with discovering phenylketonuria in 1934. He identified an unusual metabolic abnormality in the urine of two siblings with intellectual disability and linked it to phenylpyruvic acid.
What happened in the 1934 discovery of phenylketonuria?
In 1934, a Norwegian mother sought medical help for her two children, who had significant intellectual disabilities. Asbjørn Følling investigated the siblings and found phenylpyruvic acid in their urine, identifying a previously unrecognized metabolic disorder that became known as phenylketonuria.
Why is the mother important to the PKU discovery story?
The mother is important because her persistent search for an explanation brought the children's unusual condition to medical attention. Her observations and advocacy helped prompt the investigation that led Følling to identify the underlying biochemical abnormality.
What did Asbjørn Følling discover?
Følling discovered that certain children with intellectual disability excreted abnormal amounts of phenylpyruvic acid in their urine. He recognized this as evidence of a previously unknown metabolic disorder, later called phenylketonuria or PKU.
Is PKU inherited?
Yes. PKU is an inherited metabolic disorder, most commonly caused by disease-causing variants in the PAH gene. It is generally inherited in an autosomal recessive pattern, meaning an affected child typically inherits a relevant variant from both biological parents.
Why is newborn screening for PKU important?
Newborn screening can identify PKU before symptoms and severe neurological complications develop. Early diagnosis allows treatment, particularly careful management of phenylalanine intake, to begin during an important period of brain development.
The Lasting Legacy of the 1934 PKU Discovery
The most remarkable part of the Følling PKU discovery story is how far the original question traveled.
A mother wanted to understand what was happening to her children.
A physician investigated.
A strange chemical finding emerged.
A new disease was identified.
Researchers explored its inheritance and metabolism.
Dietary treatment was developed.
Newborn screening transformed diagnosis.
And a condition that once could remain invisible until devastating developmental symptoms appeared can now often be identified shortly after birth.
The entire chain began with a question.
That is why the story of PKU belongs not only in textbooks about metabolic disease, but also in the history of patient advocacy and medical discovery.
Følling's scientific contribution was extraordinary.
So was the persistence that brought the mystery to him.
The lesson is not that every unanswered medical question will lead to a historic breakthrough.
Most won't.
The lesson is that unanswered questions are worth taking seriously.
Sometimes a careful observation is the beginning of a diagnosis.
Sometimes a family pattern reveals something that has been overlooked.
Sometimes a clinician's curiosity turns an unusual symptom into a scientific clue.
And, occasionally, a parent's refusal to stop asking "Why?" becomes part of the history of medicine.
The 1934 discovery of phenylketonuria is one of those rare stories.
It reminds us that behind every medical breakthrough are real people: patients, parents, physicians, researchers, and families whose experiences help move medicine forward.
The mother asked for an explanation.
Følling looked for one.
And the answer changed medicine.
The information in this article is for educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding dietary or health concerns.